Non-Hodgkin Lymphoma Perspective

 
 
  • Two Truths and a Lie About Pathology Poor collaboration between pathologists and clinicians means both small misunderstandings and large misconceptions.
  • Chronic Lymphocytic Leukemia: 5 Things to Know The most common adult leukemia has seen a rush of new evidence in recent years. Here are some of the highlights.
  • Ureaplasma Septic Arthritis: An Unusual Case Unfolds The case of a 56-year-old woman with lymphoma in remission and now presenting with polyarthritis.
  • Does IgG4 Get on Your Nerves? The case of a 70-year-old man with IgG4-related disease that raised suspicion for cancer.
  • EHA 2019 Read clinically focused news coverage of key developments from EHA 2019
  • IWMF 2019 Read clinically focused news coverage of key developments from IWMF 2019
  • Evaluating Neck Masses in Adult and Pediatric Patients Dr Gordon Sun presents common causes of neck masses in adult and pediatric patients and discusses appropriate initial imaging studies for each patient population.
  • Let's Put Breast Implant Lymphoma Risk in Context   Dr Kathy Miller discusses the importance of placing risks in context, and questions the level of side-effect risk required for fully informed consent.
  • BSH 2019 Read clinically focused news coverage of key developments from BSH 2019
  • Linking Community and Academic Oncologists: Creating a New Model Can oncologists continue to deliver cancer care without subspecialization? Jack West envisions a team-based model that capitalizes on oncologists' unique strengths.
  • Rick Simpson Oil: Cancer Cure or Pipe Dream? He's an Internet sensation, and many cancer patients swear by his eponymous oil. But clinicians and cannabis experts are waving red flags.
  • Is Cell-Based Immunotherapy Entering the Mainstream?   Experts in cell-based therapies for cancer discuss opportunities and obstacles in their wider use beyond academic centers.
  • CAR T Cell Therapy: 'It's the Real World Now'   Drs Jacobson, Miklos, and Maus unveil 'provocative and exciting' research at ASH 2018 in CAR T cell therapy.
  • Venetoclax Shows Benefits Across a Range of Hematologic Cancers   From ASH 2018, Ann LaCasce and Jennifer Crombie from Dana-Farber discuss new trial data on venetoclax, a potent, selective inhibitor of BCL2.
  • Oncologists' Off-Label Prescribing Pits Access Against Reimbursement Off-label prescribing in oncology is undergoing a change: Payers are more restrictive in their reimbursement for off-label uses, while oncologists are keen to provide access to new immunotherapies.
  • Non-Hodgkin Lymphoma: Victory Lap   The team discusses the postinfusion period, when adverse effects are most common, and addresses remaining questions for the future of this innovative therapy.
  • 5 Things to Know About Chronotherapy With the 2017 Nobel Prize in Medicine being awarded to research on circadian rhythms, the time has come to take a look at synchronizing chemotherapy with the body's natural clock. Here are five things you should know about chronotherapy.
  • Non-Hodgkin Lymphoma: All Systems Go   The Moffitt team discusses patient referral and selection, as well as the extensive preparation candidates undergo before receiving CAR T-cell infusion.
  • Cost Problem Only Getting Worse With IO Combos, Adjuvant Use   Drs Weber and Hamid discuss the increasing cost of immune-oncology therapy, particularly concerning as the number of patients using these agents in the adjuvant setting is likely to rise greatly.
  • EHA 2018 Read clinically focused news coverage of key developments from EHA 2018